Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
- Revenue in AUD (TTM)24.25m
- Net income in AUD-144.04m
- Incorporated2004
- Employees81.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing Leads Biolabs Co Ltd | 0.00 | -58.61m | 2.29bn | 192.00 | -- | 101.37 | -- | -- | -2.00 | -2.00 | 0.00 | 0.6279 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.01 | -- | 0.7407 | -- | -100.00 | -- | 16.85 | -- | -- | -- |
| HitGen Inc | 101.94m | 23.33m | 2.48bn | 483.00 | 107.14 | 8.24 | -- | 24.31 | 0.2824 | 0.2824 | 1.24 | 3.67 | 0.2726 | 6.37 | 4.69 | 1,032,114.00 | 6.18 | 3.06 | 6.87 | 3.36 | 55.23 | 53.55 | 22.67 | 14.48 | 5.12 | 6.59 | 0.1674 | 34.32 | 14.99 | 10.08 | 26.13 | -15.65 | 3.16 | -- |
| InventisBio Co Ltd | 36.92m | -23.78m | 2.77bn | 185.00 | -- | 8.14 | -- | 75.06 | -0.2012 | -0.2012 | 0.3122 | 2.88 | 0.0988 | -- | 1.03 | 975,824.70 | -6.36 | -32.89 | -6.76 | -35.22 | 99.41 | -- | -64.41 | -682.73 | -- | -- | 0.0127 | -- | -9.02 | 25.00 | 15.41 | -- | -3.97 | -- |
| Syngene International Ltd | 580.37m | 54.93m | 2.84bn | 6.53k | 51.90 | -- | 22.95 | 4.89 | 8.72 | 8.72 | 92.16 | -- | -- | -- | -- | 5,694,474.00 | -- | 8.14 | -- | 10.44 | 75.26 | 71.29 | 9.46 | 15.03 | -- | 5.73 | -- | -- | 4.41 | 12.60 | -2.71 | 3.78 | 3.67 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 127.71m | -193.75m | 3.03bn | 1.36k | -- | 19.44 | -- | 23.69 | -2.37 | -2.37 | 1.56 | 1.90 | 0.1384 | 0.3458 | 14.57 | 441,048.00 | -21.06 | -29.90 | -36.19 | -36.18 | 88.72 | 85.56 | -152.14 | -1,188.68 | 0.8093 | -10.82 | 0.7353 | -- | 56.28 | 46.68 | 0.9031 | -- | 12.25 | -- |
| Ascentage Pharma Group International | 79.71m | -236.56m | 3.20bn | 605.00 | -- | 22.00 | -- | 40.13 | -4.01 | -4.01 | 1.35 | 2.15 | 0.1270 | 3.70 | 0.9505 | 777,727.90 | -37.68 | -30.84 | -60.56 | -41.94 | 90.87 | 94.02 | -296.81 | -252.93 | 1.53 | -- | 0.7174 | -- | 341.77 | 132.25 | 56.20 | -- | -21.49 | -- |
| Keymed Biosciences Inc | 177.99m | -52.51m | 3.20bn | 1.47k | -- | 4.91 | -- | 17.99 | -1.10 | -1.10 | 3.74 | 12.07 | 0.2068 | 0.3382 | 15.10 | 782,722.10 | -6.10 | -40.63 | -7.27 | -44.60 | 95.19 | -- | -29.48 | -593.20 | 3.74 | -- | 0.2145 | -- | 20.91 | -- | -43.38 | -- | 28.05 | -- |
| Mesoblast Ltd | 24.25m | -144.04m | 3.23bn | 81.00 | -- | 3.80 | -- | 133.00 | -0.1192 | -0.1192 | 0.0201 | 0.6583 | 0.0237 | -- | 2.25 | 299,423.60 | -14.05 | -13.19 | -15.99 | -14.68 | 70.17 | -132.14 | -593.92 | -957.40 | 1.77 | -4.50 | 0.1766 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Telix Pharmaceuticals Ltd | 940.97m | 15.64m | 3.41bn | 234.00 | 236.96 | 5.72 | 102.71 | 3.62 | 0.0425 | 0.0425 | 2.69 | 1.76 | 0.7909 | 11.01 | 7.28 | -- | 1.31 | -10.99 | 1.82 | -15.18 | 54.00 | 61.79 | 1.66 | -13.10 | 1.22 | -- | 0.4978 | -- | 54.81 | 192.25 | 851.60 | -- | 150.32 | -- |
| Sinocelltech Group Ltd | 386.00m | -63.42m | 3.70bn | 2.28k | -- | -- | -- | 9.58 | -0.6964 | -0.6964 | 4.24 | -0.1083 | 0.5458 | 0.4325 | 3.04 | 828,989.10 | -8.37 | -22.66 | -29.60 | -48.25 | 93.51 | 95.52 | -15.33 | -42.96 | 0.5008 | -0.6753 | 1.02 | -- | 33.13 | 294.24 | 127.39 | -- | 23.95 | -- |
| BeBetter Med Inc | -20.45bn | -20.45bn | 4.01bn | 150.00 | -- | 91.01 | -- | -- | -- | -- | -- | 0.4785 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0116 | -- | -- | -- | 67.59 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Mesoblast Ltd's reporting currency: Australian Dollar AUD
15.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| State Street Global Advisors, Australia, Ltd.as of 08 Dec 2025 | 44.97m | 3.51% |
| M&G Investment Management Ltd.as of 31 Oct 2025 | 40.34m | 3.14% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 34.80m | 2.71% |
| Vanguard Investments Australia Ltd.as of 31 Dec 2025 | 18.97m | 1.48% |
| Thorney Investment Group Australia Pty Ltd.as of 30 Sep 2025 | 14.12m | 1.10% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 12.25m | 0.96% |
| BlackRock Fund Advisorsas of 08 Jan 2026 | 11.91m | 0.93% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 9.03m | 0.70% |
| DFA Australia Ltd.as of 31 Dec 2025 | 7.35m | 0.57% |
| BetaShares Capital Ltd.as of 30 Jan 2026 | 7.27m | 0.57% |
More ▼
Data from 30 Jun 2025 - 06 Feb 2026Source: FactSet Research Systems Inc.
